Credit Suisse Ag Cue Biopharma, Inc. Transaction History

Credit Suisse Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.49 - $5.92 $54,872 - $130,459	-22,037 Reduced 99.93%	16 $0
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $6,495 - $18,088	1,473 Added 7.16%	22,053 $108,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $49,945 - $82,092	4,599 Added 28.78%	20,580 $232,000
Q3 2021 Nov 12, 2021	SELL	$10.06 - $15.3 $56,808 - $86,399	-5,647 Reduced 26.11%	15,981 $233,000
Q2 2021 Aug 16, 2021	SELL	$10.9 - $14.53 $14,333 - $19,106	-1,315 Reduced 5.73%	21,628 $252,000
Q1 2021 May 14, 2021	SELL	$11.2 - $16.09 $364,179 - $523,182	-32,516 Reduced 58.63%	22,943 $280,000
Q4 2020 Feb 12, 2021	SELL	$11.12 - $16.4 $35,116 - $51,791	-3,158 Reduced 5.39%	55,459 $694,000
Q3 2020 Nov 13, 2020	BUY	$15.05 - $23.54 $80,923 - $126,574	5,377 Added 10.1%	58,617 $882,000
Q2 2020 Aug 12, 2020	BUY	$12.7 - $30.73 $676,148 - $1.64 Million	53,240 New	53,240 $1.31 Million

11.9M

22K

1.2K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $47.4M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.